| Not Yet Recruiting | Role of T Lymphocytes in Hypersensitivity Reactions to Asparaginase in Patients Treated for Acute Lymphoblasti NCT07529223 | Centre Hospitalier Universitaire de Nice | N/A |
| Not Yet Recruiting | Study of Cell-free DNA in Children and Adolescents With Acute Lymphoblastic Leukemia NCT07483476 | Assistance Publique - Hôpitaux de Paris | — |
| Not Yet Recruiting | ALL Backbone in AYAs NCT07227584 | Dana-Farber Cancer Institute | Phase 2 |
| Recruiting | Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic Le NCT07191119 | St. Jude Children's Research Hospital | N/A |
| Not Yet Recruiting | Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL NCT07297914 | Bambino Gesù Hospital and Research Institute | Phase 2 / Phase 3 |
| Recruiting | Children's Laughter and Fun Yoga as Adjunctive Pain Relief Following Chemotherapy. NCT07327138 | Bahaa Bou Dargham | N/A |
| Not Yet Recruiting | Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia NCT07113132 | Safaa Ali | — |
| Not Yet Recruiting | Online Physical Activity and Health Counseling for Survivors of Childhood Acute Lymphoblastic Leukemia NCT07042932 | Rigshospitalet, Denmark | N/A |
| Recruiting | CAYA Cancer Retrospective Cohort Study NCT07246213 | Resonance, Inc. | — |
| Recruiting | Tracjectories and Predictors of Chemotherapy Induced Peripheral Neuropathy in Children With Acute Lymphoblasti NCT07326930 | The Hong Kong Polytechnic University | — |
| Recruiting | Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol NCT06882057 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 / Phase 3 |
| Recruiting | Safely Delivered Targeted High-dose Irradiation Followed by Adoptive Immunotherapy with Regulatory and Convent NCT06845592 | University Of Perugia | N/A |
| Not Yet Recruiting | An Extension Study to Evaluate the Safety and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell L NCT06721598 | National Research Center for Hematology, Russia | — |
| Recruiting | Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol NCT06764238 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 / Phase 3 |
| Completed | A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-ce NCT06705530 | National Research Center for Hematology, Russia | Phase 1 / Phase 2 |
| Completed | Reduce Sedentary Time in Acute Lymphoblastic Leukemia NCT06182163 | Children's Hospital Los Angeles | N/A |
| Recruiting | Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute NCT06608342 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Active Not Recruiting | Psychiatric Problems in Children With Acute Lymphoblastic Leukemia and Their Caregivers NCT06723496 | Assiut University | — |
| Recruiting | CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms NCT06593145 | FamiCordTx | Phase 1 |
| Recruiting | Cord Blood Transplant in Adults With Blood Cancers NCT05884333 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) NCT05291390 | Armaceutica, Inc. | Phase 2 |
| Recruiting | Bio-CAR-T BS Study NCT05366569 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | — |
| Recruiting | Bright Ideas - CIN Feasibility Study NCT04929899 | The Hospital for Sick Children | N/A |
| Completed | Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data NCT06392763 | Novartis Pharmaceuticals | — |
| Completed | Safety and Preliminary Efficacy of Donor-derived Anti-leukemia Cytotoxic T Lymphocytes for the Prevention of L NCT06865352 | Fondazione IRCCS Policlinico San Matteo di Pavia | Phase 1 / Phase 2 |
| Completed | CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI) NCT05349201 | Novartis Pharmaceuticals | — |
| Terminated | A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combi NCT04029688 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Completed | Animal Assisted Interactions With Animal Robot in the Intensive Care Unit (ICU) NCT05075395 | University of Nebraska | N/A |
| Suspended | Safety and Efficacy Evaluation of CD19-UCART NCT03229876 | Bioray Laboratories | N/A |
| Active Not Recruiting | TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in NCT03849651 | St. Jude Children's Research Hospital | Phase 2 |
| Active Not Recruiting | Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL NCT03740334 | Dana-Farber Cancer Institute | Phase 1 |
| Unknown | Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study NCT03260101 | Cellect Biotechnology | — |
| Unknown | C-CAR011 Treatment in Subjects With ALL After HSCT NCT03327285 | Peking University People's Hospital | N/A |
| Completed | A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acu NCT03181126 | AbbVie | Phase 1 |
| Completed | A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed o NCT03236857 | AbbVie | Phase 1 |
| Recruiting | International Study for Treatment of High Risk Childhood Relapsed ALL 2010 NCT03590171 | Charite University, Berlin, Germany | Phase 2 |
| Completed | Genetic Study of Familial Acute Lymphoblastic Leukemia NCT03067584 | St. Jude Children's Research Hospital | — |
| Completed | Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and M NCT02730299 | Gamida Cell ltd | Phase 3 |
| Active Not Recruiting | Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haplo NCT02790515 | St. Jude Children's Research Hospital | Phase 2 |
| Withdrawn | Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negativ NCT02647190 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Terminated | Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Res NCT02338050 | Center for International Blood and Marrow Transplant Research | Phase 2 |
| Withdrawn | Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome f NCT02269579 | Jazz Pharmaceuticals | Phase 2 |
| Completed | Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute NCT02303821 | Amgen | Phase 1 |
| Terminated | Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation NCT02259348 | St. Jude Children's Research Hospital | Phase 2 |
| Completed | Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation NCT02226861 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 |
| Completed | Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic NCT02212561 | St. Jude Children's Research Hospital | Phase 1 |
| Completed | An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Fo NCT02238925 | Jazz Pharmaceuticals | Phase 2 |
| Terminated | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Re NCT02200380 | Celldex Therapeutics | Phase 2 |
| Completed | International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010 NCT01802814 | Charite University, Berlin, Germany | Phase 3 |
| Completed | A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL NCT02046694 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | EARLY_Phase 1 |
| Completed | IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT NCT01885897 | Masonic Cancer Center, University of Minnesota | Phase 1 / Phase 2 |
| Active Not Recruiting | CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant NCT02061800 | Diane George | Phase 1 / Phase 2 |
| Completed | Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM NCT01816230 | Gamida Cell ltd | Phase 1 / Phase 2 |
| Completed | Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study NCT01735955 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders NCT01758042 | Massachusetts General Hospital | N/A |
| Terminated | A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL NCT01439347 | Spectrum Pharmaceuticals, Inc | Phase 3 |
| Completed | Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell NCT01660607 | Stanford University | Phase 1 / Phase 2 |
| Completed | Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit NCT01527838 | Fate Therapeutics | Phase 1 |
| Recruiting | A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) NCT01351545 | Center for International Blood and Marrow Transplant Research | — |
| Completed | Potential Role of CD9 and Implication of Motility Process in Pathogenesis of TEL/ALM1-positive ALL Relapses (L NCT01282593 | Rennes University Hospital | N/A |
| Completed | Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancie NCT01221857 | Gamida Cell ltd | Phase 1 / Phase 2 |
| Terminated | Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells NCT01050764 | Everett Meyer | Phase 1 / Phase 2 |
| Active Not Recruiting | Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT NCT00840853 | Baylor College of Medicine | Phase 1 |
| Unknown | Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study NCT02894645 | National University Hospital, Singapore | Phase 4 |
| Completed | Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL NCT01305655 | Nordic Society for Pediatric Hematology and Oncology | Phase 3 |
| Terminated | A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation NCT00672152 | Michael Morse, MD | Phase 1 |
| Completed | Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia NCT00495079 | Spectrum Pharmaceuticals, Inc | Phase 2 |
| Completed | Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies NCT00145613 | St. Jude Children's Research Hospital | Phase 2 |
| Available | Expanded Access to Venetoclax NCT03123029 | AbbVie | — |
| Available | CTL019 Out of Specification MAP for ALL or DLBCL Patients NCT03601442 | Novartis Pharmaceuticals | — |
| No Longer Available | MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive NCT04559555 | Novartis Pharmaceuticals | — |